UBRELVY®—the only gepant available in 50 mg and 100 mg tablets—offers patients the migraine relief they need with the flexibility they deserve1
- Taken orally, with or without food1
- Second dose can be taken at least 2 hours after the initial dose, if needed1
- The maximum daily dose is 200 mg1
- Safety established in up to 8 migraines in a 30-day period1
UBRELVY®—the only gepant available in 50 mg and 100 mg tablets—offers patients the migraine relief they need with the flexibility they deserve1
- Taken orally, with or without food1
- Second dose can be taken at least 2 hours after the initial dose, if needed1
- The maximum daily dose is 200 mg1
- Safety established in up to 8 migraines in a 30-day period1
MIGRAINE ATTACKS CAN BE UNPREDICTABLE2
Make sure your patients are ready. UBRELVY 100 mg tablets are available in a 16-count package. Eligible patients may pay as little as $0-ALL PILLS, ALL FILLS.*
*Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients
enrolled in Medicare, Medicaid, or other federal or state healthcare programs.
zero pain, sustained with a single dose1,3
Dosing considerations
Drug interactions
- UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they will cause an increase in UBRELVY exposure1
- Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of UBRELVY exposure1
- Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications. See Section 2.2 of the Prescribing Information1
- Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice; avoid second dose within 24 hours1
Use in specific populations
- Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (CLcr 15-29 mL/min): recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose1
- Avoid use in patients with end-stage renal disease (CLcr <15 mL/min)1
Use with preventive medications
- In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline.3 None of these patients were on concomitant preventive medications that act on the CGRP pathway1